Genmab As (OTCMKTS:GNMSF) – Equities research analysts at Jefferies Group lowered their FY2018 earnings per share estimates for shares of Genmab As in a research note issued to investors on Friday, according to Zacks Investment Research. Jefferies Group analyst P. Welford now expects that the company will post earnings per share of $4.27 for the year, down from their prior estimate of $4.34.
A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Genmab As from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. JPMorgan Chase & Co. cut shares of Genmab As from an “overweight” rating to a “neutral” rating in a research report on Friday, October 6th.
COPYRIGHT VIOLATION WARNING: This report was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://baseballnewssource.com/markets/analysts-issue-forecasts-for-genmab-as-fy2018-earnings-gnmsf/1818331.html.
Genmab As Company Profile
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.